Health Care

Discover why Iovance Biotherapeutics’ TIL‑based cancer immunotherapies could reshape oncology, and what its current negative P/E ratio means for investors.

Explore ImmunityBio’s battle: a biotech leader in cell & immunotherapy facing steep stock swings and a negative P/E, yet holding a $8.5 bn market cap that fuels investor hope for breakthrough cancer & disease treatments.

Vertex outperforms Regeneron with a three‑fold higher ROIC, showcasing superior capital discipline, efficient asset turnover, and a robust precision‑medicine pipeline for sustainable growth.

Thermo Fisher Scientific insider trades reveal CEO Marc N. Casper’s holdings and share activity, offering a clear view of leadership moves and stock trends.

GSK stock nears a 52‑week peak amid looming patent expirations; discover how its diverse pipeline may cushion margin pressure and drive future growth.

Cronos Group Inc. invites investors to its AGM on September 28, 2026, where audited financials, board elections, and cannabis‑industry strategy will be discussed.

FDA approves Gilead’s new HIV pill Bixlenvo, a single‑tablet combo that keeps patients suppressed and may boost the company’s market standing.

Discover how Bayer AG’s August 2026 highlights—Phase III REVEAL, Kerendia’s Japan approval, and the $7.25 bn Roundup settlement—shift its financial outlook and market prospects.

Discover how Eli Lilly’s FDA approval of Mounjaro (tirzepatide) for cardiovascular risk in type 2 diabetes gives it a unique edge over GLP‑1 rivals and boosts investor prospects.

Zeiss Meditec unveils the EVA NEXUS™ cataract configuration, adding precision‑grade presets and streamlined workflows to its retinal platform—boosting surgical control and market leadership.